Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,389.49

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,841.22 5
Food and Beverage $548.27 30

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $6,389.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.9112/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050229195 CMS
Lilly USA, LLC $22.9612/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031510001 CMS
Amgen Inc. $14.8812/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019972483 CMS
Abbott Laboratories $16.8111/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019586299 CMS
Amgen Inc. $16.4011/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020605673 CMS
AstraZeneca Pharmaceuticals LP $17.8811/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014659173 CMS
Otsuka America Pharmaceutical, Inc. $25.9610/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014764903 CMS
Amneal Pharmaceuticals LLC $12.7510/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053530405 CMS
AbbVie Inc. $26.2609/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724369 CMS
Novo Nordisk Inc $17.2509/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792141 CMS
Xeris Pharmaceuticals, Inc. $14.0708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056470115 CMS
Novartis Pharmaceuticals Corporation $22.8208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992730679 CMS
Novo Nordisk Inc $21.3008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792161 CMS
Amgen Inc. $14.4207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020605671 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.5507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057489783 CMS
AbbVie Inc. $16.5807/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724365 CMS
AbbVie Inc. $19.6606/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724359 CMS
GlaxoSmithKline, LLC. $18.5505/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001355717 CMS
Novo Nordisk Inc $20.0005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792151 CMS
AbbVie Inc. $17.6704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724353 CMS
PFIZER INC. $14.9704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050283505 CMS
PFIZER INC. $400.0004/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050014413 CMS
AbbVie Inc. $21.7004/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724347 CMS
Exact Sciences Corporation $15.7604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026641277 CMS
PFIZER INC. $3,000.0003/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049161737 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4803/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996865223 CMS
PFIZER INC. $500.0003/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049160835 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.1203/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000324347 CMS
Abbott Laboratories $24.5403/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018771569 CMS
PFIZER INC. $10.3303/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049422011 CMS
Novo Nordisk Inc $16.0802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792121 CMS
PFIZER INC. $1,541.2202/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049160829 CMS
PFIZER INC. $400.0002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049161743 CMS
AstraZeneca Pharmaceuticals LP $13.3801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014166031 CMS
Novo Nordisk Inc $17.2301/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

271 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $386.25 12/31/2023 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH LLC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998414771
Principal investigator 1 PFIZER INC. $10,480.00 12/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046366837
Principal investigator 1 PFIZER INC. $5,636.86 12/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046442637
Principal investigator 1 BioNTech SE $6,495.00 12/19/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319287
Recipient PFIZER INC. $1,040.44 12/14/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046394961
Principal investigator 1 PFIZER INC. $120,836.48 12/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046420635
Principal investigator 1 BioNTech SE $3,798.00 12/12/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319283
Principal investigator 1 PFIZER INC. $1,297.00 12/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046444691
Principal investigator 1 Bavarian Nordic A/S $1,950.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695619
Principal investigator 1 Bavarian Nordic A/S $1,000.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695679
Principal investigator 1 BioNTech SE $600.00 12/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060312917
Principal investigator 1 GRT US Holding, Inc. $1,730.47 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187491
Recipient PFIZER INC. $800.00 12/07/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046396923
Principal investigator 1 PFIZER INC. $225.00 12/07/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046445815
Principal investigator 1 GRT US Holding, Inc. $70.00 12/01/2023 Non-covered Recipient Entity
ACCELLACARE
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186663
Principal investigator 1 Bavarian Nordic A/S $8,500.00 11/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695633
Principal investigator 1 BioNTech SE $693.00 11/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319299
Principal investigator 1 GRT US Holding, Inc. $2,044.16 11/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187467
Principal investigator 1 Bavarian Nordic A/S $4,823.00 11/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695667
Principal investigator 1 BioNTech SE $600.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060312923
Principal investigator 1 BioNTech SE $300.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060312931
Principal investigator 1 BioNTech SE $300.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060312937
Principal investigator 1 BioNTech SE $693.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319289
Principal investigator 1 BioNTech SE $937.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319293
Principal investigator 1 BioNTech SE $198.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319317
Principal investigator 1 BioNTech SE $240.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319319
Principal investigator 1 GRT US Holding, Inc. $1,072.18 11/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187447
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,640.00 11/15/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095583
Principal investigator 1 PFIZER INC. $1,000.00 11/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046380847
Principal investigator 1 GRT US Holding, Inc. $1,730.47 11/07/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187423
Principal investigator 1 Bavarian Nordic A/S $56,172.00 11/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696015
Principal investigator 1 BioNTech SE $5,738.00 11/02/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319275
Principal investigator 1 GRT US Holding, Inc. $70.00 11/01/2023 Non-covered Recipient Entity
ACCELLACARE
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186595
Principal investigator 1 PFIZER INC. $2,250.00 10/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY WITH LOTIGLIPRON PF07081532 TO ASSESS CARDIOVASCULAR AND OTHER LONGTERM OUTCOMES IN ADULTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 1046429861
Principal investigator 1 Seqirus USA Inc $1,000.00 10/26/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385629
Principal investigator 1 Seqirus USA Inc $1,500.00 10/26/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385643
Principal investigator 1 BioNTech SE $5,974.00 10/25/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319295
Principal investigator 1 BioNTech SE $244.00 10/25/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319297
Principal investigator 1 GRT US Holding, Inc. $1,730.47 10/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187311
Principal investigator 1 GRT US Holding, Inc. $250.00 10/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187335
Principal investigator 1 GRT US Holding, Inc. $2,800.00 10/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187359
Principal investigator 1 GRT US Holding, Inc. $6,072.27 10/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187381
Principal investigator 1 GRT US Holding, Inc. $2,024.09 10/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187401
Principal investigator 1 PFIZER INC. $113.40 10/20/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046427857
Principal investigator 1 GRT US Holding, Inc. $250.00 10/19/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187267
Principal investigator 1 GRT US Holding, Inc. $2,800.00 10/19/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187287
Principal investigator 1 Seqirus USA Inc $1,922.25 10/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385613
Principal investigator 1 Seqirus USA Inc $1,922.25 10/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385764
Principal investigator 1 BioNTech SE $5,012.00 10/17/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319285
Principal investigator 1 Eli Lilly and Company $97,229.00 10/17/2023 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038122621
Principal investigator 1 GRT US Holding, Inc. $1,072.18 10/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187245
Principal investigator 1 PFIZER INC. $27,115.52 10/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046423511
Principal investigator 1 Bavarian Nordic A/S $9,168.00 10/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695839
Principal investigator 1 Bavarian Nordic A/S $40,619.00 10/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695799
Principal investigator 1 BioNTech SE $3,113.00 10/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319281
Principal investigator 1 BioNTech SE $4,352.00 10/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319277
Principal investigator 1 BioNTech SE $3,798.00 10/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319279
Principal investigator 1 Bavarian Nordic A/S $1,966.00 09/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695945
Principal investigator 1 BioNTech SE $5,877.00 09/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313409
Principal investigator 1 GRT US Holding, Inc. $1,072.18 09/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187223
Principal investigator 1 PFIZER INC. $278.10 09/16/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046402325
Principal investigator 1 PFIZER INC. $400.00 09/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046404605
Principal investigator 1 Bavarian Nordic A/S $1,484.00 09/14/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695659
Principal investigator 1 Bavarian Nordic A/S $151.00 09/14/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696021
Principal investigator 1 PFIZER INC. $403.92 09/13/2023 Non-covered Recipient Entity
AccellacareRaleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046414449
Principal investigator 1 GRT US Holding, Inc. $1,072.18 09/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187203
Principal investigator 1 PFIZER INC. $14,609.70 09/09/2023 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046406353
Principal investigator 1 Bavarian Nordic A/S $1,855.00 09/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695647
Principal investigator 1 Bavarian Nordic A/S $1,913.00 09/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695739
Principal investigator 1 BioNTech SE $5,045.00 09/06/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313407
Principal investigator 1 BioNTech SE $300.00 09/06/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313417
Principal investigator 1 PFIZER INC. $34,055.07 09/02/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046406505
Principal investigator 1 BioNTech SE $6,154.00 09/01/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313405
Principal investigator 1 GRT US Holding, Inc. $1,072.18 09/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187179
Principal investigator 1 PFIZER INC. $403.92 09/01/2023 Non-covered Recipient Entity
AccellacareRaleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046421779
Recipient PFIZER INC. $3,186.74 08/30/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046446273
Principal investigator 1 PFIZER INC. $4,459.05 08/24/2023 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046430405
Principal investigator 1 Bavarian Nordic A/S $10,654.00 08/23/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695959
Principal investigator 1 BioNTech SE $3,798.00 08/23/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318149
Principal investigator 1 GRT US Holding, Inc. $13,408.84 08/23/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187157
Principal investigator 1 PFIZER INC. $982.80 08/23/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046422379
Principal investigator 1 PFIZER INC. $1,945.24 08/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046427533
Principal investigator 1 Bavarian Nordic A/S $7,753.00 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695891
Principal investigator 1 Becton, Dickinson and Company $1,877.58 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
SUST030 No dispute reported 06/30/2026 1039322621
Principal investigator 1 BioNTech SE $2,176.00 08/18/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319029
Principal investigator 1 GRT US Holding, Inc. $85.50 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187107
Principal investigator 1 GRT US Holding, Inc. $2,800.00 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187137
Principal investigator 1 PFIZER INC. $2,071.44 08/17/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046435425
Principal investigator 1 PFIZER INC. $1,500.00 08/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046401707
Principal investigator 1 PFIZER INC. $5,027.05 08/11/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046422319
Principal investigator 1 PFIZER INC. $174.15 08/11/2023 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046432727
Principal investigator 1 Bavarian Nordic A/S $19,110.00 08/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695779
Principal investigator 1 BioNTech SE $9,536.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317339
Principal investigator 1 BioNTech SE $200.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318161
Principal investigator 1 BioNTech SE $1,500.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319011
Principal investigator 1 BioNTech SE $750.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319015
Principal investigator 1 BioNTech SE $750.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319021
Principal investigator 1 BioNTech SE $600.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319023
Principal investigator 1 PFIZER INC. $2,429.04 08/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046399291
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,248.00 08/02/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095561
Principal investigator 1 GRT US Holding, Inc. $250.00 08/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187065
Principal investigator 1 GRT US Holding, Inc. $4,648.18 08/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187087
Principal investigator 1 Bavarian Nordic A/S $15,236.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695983
Principal investigator 1 BioNTech SE $4,872.00 07/26/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318155
Principal investigator 1 BioNTech SE $693.00 07/26/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319031
Principal investigator 1 BioNTech SE $9,120.00 07/26/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319035
Principal investigator 1 PFIZER INC. $1,500.00 07/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046407185
Principal investigator 1 PFIZER INC. $3,231.23 07/26/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046510166
Principal investigator 1 PFIZER INC. $4,949.21 07/20/2023 Non-covered Recipient Entity
ACELLACARE US INC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046446259
Principal investigator 1 PFIZER INC. $871.43 07/20/2023 Non-covered Recipient Entity
ACELLACARE US INC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046446489
Principal investigator 1 PFIZER INC. $8,158.59 07/19/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046464905
Principal investigator 1 Bavarian Nordic A/S $22,205.00 07/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695901
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 07/18/2023 Non-covered Recipient Entity
PMG RESEARCH
Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease No dispute reported 06/30/2026 1017235441
Principal investigator 1 Bavarian Nordic A/S $59,927.00 07/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695809
Principal investigator 1 PFIZER INC. $19,500.00 07/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046492079
Principal investigator 1 PFIZER INC. $12,690.48 07/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046348823
Principal investigator 1 Bavarian Nordic A/S $5,841.00 07/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695719
Principal investigator 1 BioNTech SE $4,352.00 07/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318157
Principal investigator 1 BioNTech SE $6,667.00 07/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318159
Principal investigator 1 GRT US Holding, Inc. $6,168.33 07/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187019
Principal investigator 1 GRT US Holding, Inc. $1,072.18 07/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187043
Principal investigator 1 PFIZER INC. $690.48 06/29/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046529261
Principal investigator 1 Bavarian Nordic A/S $15,293.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695989
Principal investigator 1 BioNTech SE $16,032.00 06/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319103
Principal investigator 1 GRT US Holding, Inc. $4,048.18 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186977
Principal investigator 1 GRT US Holding, Inc. $4,048.18 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186997
Principal investigator 1 PFIZER INC. $9,462.15 06/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046347443
Principal investigator 1 PFIZER INC. $9,019.59 06/22/2023 Non-covered Recipient Entity
ACELLACARE US INC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046418329
Principal investigator 1 PFIZER INC. $345.24 06/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046527297
Recipient Eli Lilly and Company $1,390.43 06/21/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038052143
Principal investigator 1 PFIZER INC. $2,374.06 06/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046517485
Principal investigator 1 Bavarian Nordic A/S $13,363.00 06/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695931
Principal investigator 1 BioNTech SE $2,176.00 06/20/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319099
Principal investigator 1 PFIZER INC. $4,488.12 06/16/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046515309
Principal investigator 1 PFIZER INC. $1,158.98 06/15/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046499447
Principal investigator 1 PFIZER INC. $14,153.00 06/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046514495
Principal investigator 1 PFIZER INC. $200.00 06/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046529893
Principal investigator 1 Eli Lilly and Company $238.29 06/14/2023 Non-covered Recipient Entity
TRIANGLE MEDICAL RESEARCH ASSOCIATES LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038137753
Principal investigator 1 PFIZER INC. $6,559.56 06/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046519005
Principal investigator 1 Bavarian Nordic A/S $10,850.00 06/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695831
Principal investigator 1 BioNTech SE $6,251.00 06/13/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319093
Principal investigator 1 Eli Lilly and Company $1,945.21 06/13/2023 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038136187
Principal investigator 1 GRT US Holding, Inc. $1,072.18 06/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186907
Principal investigator 1 Bavarian Nordic A/S $14,320.00 06/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695751
Principal investigator 1 BioNTech SE $8,649.00 06/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060315043
Principal investigator 1 GRT US Holding, Inc. $5,096.15 06/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186885
Principal investigator 1 PFIZER INC. $1,105.65 06/02/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046525859
Principal investigator 1 Becton, Dickinson and Company $3,000.00 06/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
SUST030 No dispute reported 06/30/2026 1039322345
Principal investigator 1 Bavarian Nordic A/S $12,330.00 05/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696003
Principal investigator 1 BioNTech SE $4,075.00 05/30/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319105
Principal investigator 1 GRT US Holding, Inc. $1,072.18 05/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186863
Principal investigator 1 PFIZER INC. $29,657.28 05/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046445883
Principal investigator 1 PFIZER INC. $400.73 05/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046521679
Principal investigator 1 Bavarian Nordic A/S $9,864.00 05/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695965
Principal investigator 1 BioNTech SE $6,251.00 05/24/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319101
Principal investigator 1 GRT US Holding, Inc. $5,096.15 05/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186839
Principal investigator 1 Bavarian Nordic A/S $9,053.00 05/19/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695911
Principal investigator 1 Bavarian Nordic A/S $10,888.00 05/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695871
Principal investigator 1 BioNTech SE $12,931.00 05/16/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319095
Principal investigator 1 PFIZER INC. $6,904.80 05/16/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046525049
Principal investigator 1 Janssen Pharmaceuticals, Inc $24,823.00 05/12/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095537
Principal investigator 1 Bavarian Nordic A/S $530.00 05/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696009
Principal investigator 1 PFIZER INC. $74,759.53 05/10/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046368707
Principal investigator 1 PFIZER INC. $966.60 05/10/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046440087
Principal investigator 1 Bavarian Nordic A/S $9,212.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695771
Principal investigator 1 BioNTech SE $1,684.00 05/09/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319089
Principal investigator 1 Esperion Therapeutics, Inc. $120.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050735109
Principal investigator 1 GRT US Holding, Inc. $5,216.42 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186817
Principal investigator 1 PFIZER INC. $24,857.28 05/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046520055
Principal investigator 1 PFIZER INC. $2,103.65 05/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046371203
Principal investigator 1 Seqirus USA Inc $400.00 05/04/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385719
Principal investigator 1 Seqirus USA Inc $400.00 05/04/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386497
Principal investigator 1 Seqirus USA Inc $400.00 05/04/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386513
Principal investigator 1 Seqirus USA Inc $400.00 05/04/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386527
Principal investigator 1 Seqirus USA Inc $400.00 05/04/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386541
Principal investigator 1 Bavarian Nordic A/S $16,154.00 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695699
Principal investigator 1 BioNTech SE $8,000.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313659
Principal investigator 1 BioNTech SE $19,622.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319083
Principal investigator 1 BioNTech SE $1,899.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319085
Principal investigator 1 BioNTech SE $2,000.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319119
Principal investigator 1 GRT US Holding, Inc. $2,024.09 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186795
Principal investigator 1 PFIZER INC. $3,452.40 04/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046475466
Principal investigator 1 Bavarian Nordic A/S $15,700.00 04/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695977
Principal investigator 1 PFIZER INC. $1,472.85 04/26/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046446343
Principal investigator 1 Esperion Therapeutics, Inc. $400.00 04/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050734439
Principal investigator 1 Esperion Therapeutics, Inc. $2,000.00 04/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050734451
Principal investigator 1 Esperion Therapeutics, Inc. $1,500.00 04/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050734457
Principal investigator 1 Esperion Therapeutics, Inc. $1,000.00 04/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050734463
Principal investigator 1 Esperion Therapeutics, Inc. $530.00 04/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050734469
Principal investigator 1 PFIZER INC. $3,205.84 04/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046438991
Principal investigator 1 PFIZER INC. $1,611.90 04/22/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046479303
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,500.00 04/21/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095539
Principal investigator 1 PFIZER INC. $5,445.75 04/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046438975
Principal investigator 1 Seqirus USA Inc $859.40 04/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385703
Principal investigator 1 Seqirus USA Inc $859.40 04/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386183
Principal investigator 1 Seqirus USA Inc $859.40 04/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386201
Principal investigator 1 Seqirus USA Inc $859.40 04/19/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386217
Principal investigator 1 Bavarian Nordic A/S $22,738.00 04/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695881
Principal investigator 1 BioNTech SE $2,592.00 04/18/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319097
Principal investigator 1 GRT US Holding, Inc. $6,168.33 04/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186769
Principal investigator 1 Bavarian Nordic A/S $8,461.00 04/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695821
Principal investigator 1 BioNTech SE $8,351.00 04/13/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319091
Principal investigator 1 PFIZER INC. $413.74 04/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046480193
Principal investigator 1 PFIZER INC. $4,225.10 04/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046478683
Principal investigator 1 Bavarian Nordic A/S $25,930.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695709
Principal investigator 1 Bavarian Nordic A/S $1,200.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696027
Principal investigator 1 Bavarian Nordic A/S $7,500.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988696033
Principal investigator 1 BioNTech SE $19,693.00 04/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319087
Principal investigator 1 PFIZER INC. $2,918.70 03/31/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046459687
Principal investigator 1 Bavarian Nordic A/S $16,078.00 03/29/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695995
Principal investigator 1 Esperion Therapeutics, Inc. $13,179.70 03/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 1050733809
Principal investigator 1 PFIZER INC. $400.73 03/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046451587
Principal investigator 1 PFIZER INC. $168.75 03/22/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046468493
Principal investigator 1 Bavarian Nordic A/S $11,953.00 03/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695939
Principal investigator 1 BioNTech SE $4,214.00 03/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319041
Principal investigator 1 Bavarian Nordic A/S $67,983.00 03/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695849
Principal investigator 1 BioNTech SE $8,558.00 03/15/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319049
Principal investigator 1 GRT US Holding, Inc. $6,600.00 03/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186749
Principal investigator 1 ABBVIE INC. $9,546.55 03/09/2023 Non-covered Recipient Entity
ACELLACARE US INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998373635
Principal investigator 1 PFIZER INC. $2,466.00 03/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046434675
Principal investigator 1 PFIZER INC. $1,339.20 03/09/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046448683
Principal investigator 1 PFIZER INC. $3,283.89 03/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046455751
Principal investigator 1 Janssen Pharmaceuticals, Inc $628.00 03/03/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095481
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385673
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385687
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385915
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385929
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385945
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385959
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385975
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021385993
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386008
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386023
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386037
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386051
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386067
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386081
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386095
Principal investigator 1 Seqirus USA Inc $859.40 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386111
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386125
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386139
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386153
Principal investigator 1 Seqirus USA Inc $345.24 03/01/2023 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1021386169
Principal investigator 1 BioNTech SE $24,475.00 02/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319055
Principal investigator 1 PFIZER INC. $32,058.00 02/28/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046448819
Principal investigator 1 Janssen Pharmaceuticals, Inc $111,826.00 02/23/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095489
Principal investigator 1 Bavarian Nordic A/S $13,794.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695951
Principal investigator 1 PFIZER INC. $1,260.90 02/22/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046453023
Principal investigator 1 PFIZER INC. $15,133.02 02/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046452683
Principal investigator 1 PFIZER INC. $4,737.46 02/17/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046456563
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $4,070.38 02/16/2023 Non-covered Recipient Entity
ACELLACARE US INC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046548592
Principal investigator 1 Bavarian Nordic A/S $16,758.00 02/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695861
Principal investigator 1 Bavarian Nordic A/S $11,568.00 02/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695761
Principal investigator 1 PFIZER INC. $48,840.50 02/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046451925
Principal investigator 1 Bavarian Nordic A/S $27,405.00 02/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695689
Principal investigator 1 PFIZER INC. $1,838.70 01/27/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046538149
Principal investigator 1 Bavarian Nordic A/S $23,824.00 01/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695971
Principal investigator 1 Janssen Pharmaceuticals, Inc $29,552.00 01/25/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095485
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,420.00 01/25/2023 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH PMG RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1017234041
Principal investigator 1 PFIZER INC. $1,930.50 01/25/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046542211
Principal investigator 1 PFIZER INC. $400.73 01/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046532917
Principal investigator 1 Bavarian Nordic A/S $23,471.00 01/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695921
Principal investigator 1 GRT US Holding, Inc. $2,000.00 01/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186705
Principal investigator 1 GRT US Holding, Inc. $7,000.00 01/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054186727
Principal investigator 1 PFIZER INC. $8,647.44 01/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046545207
Principal investigator 1 Novartis Pharmaceuticals Corporation $520.17 01/15/2023 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1017204289
Principal investigator 1 PFIZER INC. $6,887.70 01/12/2023 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1046546795
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,790.00 01/11/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095479
Principal investigator 1 PFIZER INC. $2,655.06 01/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046538455
Principal investigator 1 Bavarian Nordic A/S $867.00 01/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695789
Principal investigator 1 Bavarian Nordic A/S $109,958.00 01/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988695729